NIH-CAP 2005-06 Participating Companies - 11/2007
NIH-CAP 2005-06 Participating Companies
[pic]
|21st Century Medicine, Inc. |Dean Barry |
|Rancho Cucamonga, CA |Tel: 909-466-8633 |
| |Email: jdbarry@ |
| |
|21st Century Medicine, Inc. has developed novel technologies for cryopreservation and long-term storage of biological tissue |
|slices. Tissue slices are used pervasively during pharmaceutical drug discovery and development, however their use is |
|problematic. Because these tissues can not currently be effectively stored, extensive on-site live animal preparations are |
|required. 21st Century Medicine is currently validating cryopreserved neural, kidney, liver, and intestinal tissue for ADME/Tox |
|testing applications. |
|Ready-to-use tissue slices configured for specific testing requirements will significantly increase throughput, reduce on-site |
|testing costs, reduce variation, and further the potential for analytical standardization. Preservation systems for clinical |
|applications are also under development. |
[pic]
|ABIOMED, Inc. |Robert Stewart |
|Danvers, MA |Tel: 847-491-3280 |
| |Email: rstewart@ |
| |
|ABIOMED, Inc. is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping |
|function of the failing heart. ABIOMED currently manufactures and sells the AB5000™ Circulatory Support System and the BVS® 5000|
|Biventricular Support System for the temporary support of all patients with failing but potentially recoverable hearts. In |
|Europe, ABIOMED offers the Impella® Recover™ minimally invasive cardiovascular support systems under CE Mark approval. The |
|Company’s AbioCor® Implantable Replacement Heart is the subject of an initial clinical trial being conducted under an |
|Investigational Device Exemption from the United States Food and Drug Administration. |
[pic]
|Acme Express, Inc. |Don Scipione |
|Cleveland, OH |Tel: 216-391-7400 |
| |Email: dscipione@ |
| |
|Acme Express, Inc. develops healthcare staff scheduling software that cuts schedule-making costs by 80%, optimizes the schedule,|
|and eliminates paper work. Doctors On Call Schedule (DOCS) Request Module mitigates the “negotiations” between staff and the |
|off-time administrator. Generator Module optimizes a fair and accurate schedule. Consolidation Module standardizes and |
|consolidates the entire enterprise call schedule. DOCS eliminates schedule inequity and frees senior medical staff to focus on |
|healthcare delivery rather than contentious scheduling issues. |
|Our mission is to dramatically increase the productivity of healthcare schedulers. |
|Our vision is to be recognized as the pioneer in web-enabled medical staff scheduling worldwide. |
[pic]
|Adherence Technologies |Alan Letzt |
|Dulles, VA |Tel: 703-674-5408 |
| |Email: ALetzt@ |
| |
|Adherence Technologies has developed AccuNurse™, a voice-activated and hands-free system that is revolutionizing long-term care |
|staff documentation, education, and communication. AccuNurse integrates cutting-edge speech recognition, VoIP and Internet |
|technologies with its own proprietary software that further improves speech recognition accuracy and promotes extreme ease of |
|use. We also develop interfaces between AccuNurse, clinical software, other wireless systems, and the facility’s main phone |
|system. We install a turnkey system, train the trainers, and provide outstanding client support for this transformation |
|technology. AccuNurse benefits include dramatically improving quality of care and risk management while reducing nursing home |
|costs. |
[pic]
|Advanced Brain Monitoring, Inc. |Chris Berka |
|Carlsbad, CA |Tel: 760-720-0099 |
| |Email: chris@b- |
| |
|Advanced Brain Monitoring, Inc. develops and delivers innovative solutions for sleep apnea diagnosis, memory dysfunction |
|measurement and alertness monitoring. Advanced Brain Monitoring helps clinicians provide better patient care at lower cost with|
|products that combine laboratory level accuracy with the portability, ease of use and affordability of consumer electronics. |
|The company has chosen to focus on the highly prevalent, underdiagnosed OSA, but Advanced Brain Monitoring systems are |
|applicable to other sleep and neurological disorders. Advanced Brain Monitoring systems make possible the widespread use by |
|physicians, dentists, industrial/transportation companies, and consumers. |
[pic]
|Aerophase, Inc. |Brian Hansen |
|Longmont, CO |Tel: 847-491-3287 |
| |Email: Aerophase@ |
| |
|Aerophase Inc. has developed a new Metered Dose Inhaler (MDI) that uses a better propellant and aerosol valve. Most MDIs used |
|to treat asthma still use CFC (chlorofluorocarbon) propellants and all CFC MDIs will be removed from the market to comply with |
|international environmental laws to stop all CFC production. The new HFA (hydrofluoroalkane) propellant MDIs cost 3-5 times the|
|CFC propellant MDIs. The Aerophase MDI is superior to CFC and HFA MDIs with better dose control, higher drug delivery |
|efficiency, less than 1% of the current propellant cost and less than 0.1 % of the environmental impact. |
[pic]
|Agave BioSystems, Inc. |Noe Salazar |
|Austin, TX |Tel: 512-671-1369 |
| |Email: nsalazar@ |
| |
|Agave BioSystems has broad capabilities in molecular and microbiology as well as microfabricated and nanoscale systems. The |
|company’s sophisticated laboratories are complemented with access to a broad range of research and development tools and |
|facilities at Cornell University. Recently we have made important developments in flow cytometry that will lead to two product |
|lines: A suite of novel assays are currently being developed that utilize microspheres and quantum dots. The advantages of |
|these assays are both improved sensitivity and multiplexing capabilities. Additionally, a simple yet flexible |
|microscope-mountable flow cytometry instrument has been developed. This instrument provides a low-cost alternative to |
|conventional flow cytometers and enables new experimentation. |
[pic]
|Alan Penn & Associates, Inc. |Alan Penn |
|Rockville, MD |Tel: 847-491-3281 |
| |Email: apenn@ |
| |
|Alan Penn & Associates, Inc. develops and commercializes cutting-edge diagnostic image tools that enable clinicians to improve |
|outcomes by detecting cancers earlier and more accurately. Our initial product, CADimas™, is the first FDA-cleared |
|computer-aided-detection (CAD) system for breast MRI that helps radiologists screen for and diagnose breast cancer using both |
|lesion shape (morphology) and timing of contrast uptake (kinetics). R&D has been conducted in collaboration with leading |
|researchers and clinicians at eight major institutions and funded with $3.0M in SBIR grants from National Cancer Institute. |
|CADimas™ is currently in beta testing. IP is protected by patents and trade secrets. |
[pic]
|Ambergen Inc. |Richard DelMastro |
|Waltham, MA |Tel: 847-491-3276 |
| |Email: rdm@ |
| |
|AmberGen Inc is a molecular diagnostics company focusing on the development of innovative high-value diagnostics for complex |
|diseases. Our research is based on the relationship of disease phenotype with changes in regional and global methylation that |
|occur at the DNA level. We have exploited this phenomenon and developed assays for the early diagnosis of lung cancer and to |
|improve the categorization and treatment of asthma. We have identified novel Asthma DNA methylation biomarkers (AsDMBs) and |
|applied them within a non-invasive, cost effective and easy to use diagnostic format. The patented prototype diagnostic assay |
|is being validated in a clinical study. |
[pic]
|AnaBus |Richard Waterman |
|Jenkintown, PA |Tel: 215-576-8447 |
| |Email: richard_waterman@ |
| |
|AnaBus synthesizes technological and analytic advances to create efficient and original solutions in the areas of marketing |
|technology, software development and business analytics. Driven by innovation, we apply technology to perform complicated |
|analytics with greater clarity, disseminate information more widely, and solve problems more cost-effectively for our clients. |
|Recent projects: |
|-created online surveys for market research projects, performing the development, hosting, recruiting, and statistical analysis |
|in-house. |
|-developed an online analytics software platform implementing the propensity scores methodology |
|-developed automated ATM survey respondent compensation system -ran a national sample, large scale data collection and business |
|analytics project. |
[pic]
|APD Life Sciences |Roy Hammerstedt |
|State College, PA |Tel: 814-234-4835 |
| |Email: hammer@ |
| |
|ADP Life Sciences, Inc. developed a disposable detector for assessing conditions within a variety of sealed containers. We |
|offer this patent-protected, non-invasive, low-cost detector under sublicense agreement for biomanufacturing applications. |
|Based upon fluorescent bioindicators, this detector allows for immediate assessment of internal pH, oxygen tension and microbial|
|contamination, and is useful for (a) conformance with developing regulatory requirements for PAT protocols; (b) adjustment of |
|processes for optimum product production; and (c) early detection of undesired organisms. Given our exceptionally broad |
|experience in many applications, we can work with the licensee to validate and optimize prototypes and protocols. |
[pic]
|ApoLife, Inc. |Nalini Motwani |
|Detroit, MI |Tel: 313-446-2625 |
| |Email: nmotwani@ |
| |
|ApoLife has developed platform expression technologies for the rapid and cost-effective screening and production of recombinant |
|proteins and fully functional human antibodies. The market for therapeutic antibodies is expected to grow to $30 billion by |
|2010. ApoLife’s yeast system has applications in (I) acceleration of antibody screening and discovery from either hybridoma |
|subclones or phage display libraries, (II) cost-effective production of recombinant proteins and antibodies. |
| |
|ApoLife’s process requires 1/3 the time for production, thus lowering the cost of capital investment, and has the potential of |
|lowering the cost of final products by up to 50%. The company employs Bakers yeast, S. cerevisiae, which has been used for |
|manufacturing of several FDA approved therapeutic products thus providing regulatory competitive advantages over other alternate|
|expression systems. By applying ApoLife’s proprietary “Twin Cassette” expression system, biopharma and biotechnology companies |
|can accelerate the process of bringing the new therapies to market and help reduce the healthcare costs. |
[pic]
|Artann Laboratories |Noune Sarvazyan |
|Trenton, NJ |Tel: 512-996-8565 |
| |Email: nsarvaz@ |
| |
|Artann Laboratories, Inc. (Artann) is an innovative research company developing a wide range of novel biomedical technologies |
|and products. Patented inventions of Artann include a variety of imaging modalities: mechanical imaging, new approaches to |
|ultrasonic and magnetic resonance elasticity imaging, and shear wave elasticity imaging. Artann also introduced several new |
|medical diagnostic devices, including skin elasticity analyzer, muscle water content tester, colonoscopy force monitor, and a |
|portfolio of scanning bone ultrasonometers. A new area of Artann research is biomedical and industrial applications of the time|
|reversal acoustics. |
[pic]
|Atom Sciences, Inc. |Tom Whitaker |
|Oak Ridge, TN |Tel: 865-483-1113 |
| |Email: whitaker@atom- |
| |
|Atom Sciences, Inc. (ASI) was founded in 1980. Its original charter was to commercialize a laser-based analytical technology |
|called resonance ionization spectroscopy (RIS) that was developed at Oak Ridge National Laboratory. The company operated for |
|several years as an RIS analytical instrumentation and service company. From this highly specialized market, the company |
|diversified into the designing and installing custom Time-of-Flight (TOF) mass spectrometers. Based on its work in TOF analysis |
|of DNA microarrays, the Company has recently begun developing new technologies related to improving the way genetic information |
|is acquired. |
[pic]
|Azevan Pharmaceuticals, Inc. |Neal Simon |
|Bethlehem, PA |Tel: 610-419-1057 |
| |Email: ngsimon@ |
| |
|Azevan Pharmaceuticals is a drug discovery and development company producing novel therapeutics for disorders of stress, mood, |
|and behavior. The first series of clinical candidates selectively block the effects of arginine vasopressin (AVP), a naturally |
|occurring chemical signal in the body involved in the pathophysiology of conditions that include stress-related affective |
|illness, impulsivity/inappropriate aggression, and menstrual-related disorders. The chemistry platform can be manipulated to |
|target other G-protein coupled receptors, including high value targets such as the cannabinoid-1 receptor for addiction and |
|obesity. The receptors targeted by Azevan are also implicated in certain cancers and cardiovascular disease. |
[pic]
|BCR Diagnostics |Boris Rotman |
|Jamestown, RI |Tel: 401-849-9957 |
| |Email: bcrbiotech@ |
| |
|BCR Diagnostics has developed a unique biosensor (termed "80K-biochip") based on using engineered spores as fluorogenic |
|nanodetectors. The disposable 80K-biochip provides an optimal combination of speed, specificity, sensitivity, and cost |
|effectiveness that is currently unmatched by any other device. |
|An advanced application of the 80K-biochip is for detecting contaminating bacteria in platelets intended for transfusion. Other|
|applications include sterility assurance, detection of weaponized biological particles, and environmental monitoring. |
|A prototypic biosensor has the following specifications: |
| 1. Sensitivity to individual biological particles |
| 2. Testing time of about 15 minutes |
| 3. Cost-effective testing based on disposable biochips |
| 4. Cost-effective instrumentation |
[pic]
|BioAssessments, LLC |Christopher Hyde |
|Elkton, MD |Tel: 410-398-1993 |
| |Email: chyde@ |
| |
|BioAssessments is developing a promising biological marker into a useful assessment technique. The initial clinical |
|applications include assessing such diverse medical concerns as attention problems and hypertension. The value of our product |
|lies in: a) reducing trial-and-error in selecting medications; b) more efficient titration of medications; and c) identifying |
|individuals who might respond adversely to medications. Our technology could also be used as an alertness monitor for operators|
|performing mission-critical tasks in military and industrial operations. BioAssessments currently builds custom monitoring |
|systems and provides extensive analytical services for researchers at major universities and hospitals to measure this |
|biological marker. |
[pic]
|BioDetection Instruments |Gregory Magness |
|Fayetteville, AR |Tel: 847-491-3282 |
| |Email: gmagness@virtual- |
| |
|'BioDetection Instruments, LLC was formed in 2002 to commercialize technology for the rapid detection of food pathogens. Its |
|intellectual property portfolio forms a set of instrumentation characteristics that greatly improve the speed of detection, |
|lower detection limits, and provide quantitative results. The instrumentation under development is designed for tabletop use in|
|a processing plant environment with minimal operator training requirements. The company's mission is to improve the safety and |
|quality of world food supplies through high-performance biosensors, assay kits, and instruments for the rapid detection of food |
|pathogens and chemical residues. |
[pic]
|Biomedical Acoustics Research Company |Richard Sandler |
|Evanston, IL |Tel: 847-332-2217 |
| |Email: rhsandler@ |
| |
|The Biomedical Acoustics Research Company develops innovative medical diagnostic modalities based on multi-sensor |
|computer-assisted auscultation (“intelligent stethoscopes”). Our technologies simply and instantly provide useful, accurate and|
|low cost information from painless, safe and portable units. We combine cutting edge digital signal processing, sensor and |
|computer technology with compassionate and informed medical knowledge to help meet important medical market needs. We’re |
|passionate about the tremendous opportunities for implementing these techniques to assist in the diagnosis of many |
|gastrointestinal, pulmonary, musculoskeletal, and cardiovascular conditions. |
[pic]
|Biomedical Development Corporation |Phyllis Siegel |
|San Antonio, TX |Tel: 210-308-0636 |
| |Email: psiegel@ |
| |
|Frio Technologies is a specialty pharmaceutical company dedicated to treating and preventing infections transmitted through the |
|oral cavity. This is an important emerging market with no market leader. It is believed by many that the oral cavity is a |
|route to infection leading to stroke, heart disease, diabetes, rheumatoid arthritis, and causing infections in cancer patients, |
|organ transplant recipients, and others. |
|Our first product is an oral rinse to treat gingivitis, which is often the first clinical symptom of disease. We have |
|successfully completed Phase I safety studies and are seeking investment for Phase 2 efficacy and toxicology studies. |
[pic]
|Bioscience Development Inc |Steven Schutzer |
|New York, NY |Tel: 973-972-4872 |
| |Email: grants@ |
| |
|The Company is dedicated to developing diagnostic assays in immunologic and infectious diseases, including Lyme disease, that |
|will be useful to guide therapeutic decisions for humans and animals. |
[pic]
|Biostat |Michael Borenstein |
|Englewood, NJ |Tel: 201-541-5688 |
| |Email: MichaelB@ |
| |
|Our company develops software for use in research. The software is used by pharmaceutical companies, universties, and other |
|research organizations. |
[pic]
|BioTechPlex Corporation |Donovan Yeates |
|San Diego, CA |Tel: 858-455-9031 |
| |Email: dyeates@ |
| |
|To address the need for new respiratory and cardiac drugs, BioTechPlex/Ceraltics provides cell based HTS screening services and |
|target validation. Through the simultaneous measurements of multiple fluorophores, MAPR provides dynamic fingerprints of the |
|interaction of the “drug” with the cellular target site. It is 1000 times faster than competitive systems, yet has a higher |
|sensitivity and specificity. Drug discovery is further enhanced through screening of “pathogenic” engineered cell lines for |
|asthma and COPD. Target sites are validated with cell culture-based systems for ciliary activity, water transport, cardiac |
|myocyte beat rate and QT interval. We predict profitability in the 3rd year. |
[pic]
|Calibrant Biosystems |Don DeVoe |
|Gaithersburg, MD |Tel: 301-977-7900 |
| |Email: don.devoe@ |
| |
|Calibrant Biosystems, Inc. discovers, develops, and commercializes protein biomarkers for the diagnosis and treatment of human |
|disease. Calibrant’s targeted approach to biomarker discovery provides competitive advantage through proprietary proteomics |
|technologies which are uniquely compatible with limited clinical tissue samples. The company’s strategy is based on developing a|
|robust biomarker patent portfolio through targeted collaborations with leading clinical researchers, and biomarker out-licensing|
|to established pharmaceutical and diagnostics companies. |
[pic]
|Callida Genomics, Inc. |Ana Drmanac |
|Sunnyvale, CA |Tel: 408-838-9539 |
| |Email: rade@ |
| |
|Callida Genomics, Inc. develops and sells advanced whole gene and genome resequencing products and services using proprietary |
|ProbeUniverseTM and combinatorial SBH technologies. Universal Array based HyChip® and SingleMoleculeGenomeChip have broad |
|applications in research, drug development, and diagnostics for personalized medicine. Universal Array based HyChip® enables |
|reads of 6kb long sequences in a simple two-hour bench assay at lower cost. The HyChip® system further enables high |
|re-sequencing throughput with one inexpensive standard array scanner. |
[pic]
|CCC Diagnostics LLC |Paul Tso |
|Baltimore, MD |Tel: 410-633-4885 |
| |Email: paul@ |
| |
|CCC Diagnostics LLC (CCCD) is developing a medical diagnostics technology to establish drug response guides for selection of |
|effective chemotherapy. This information aids physicians in determining a personalized treatment regimen effective for |
|individual cancer patients. The service provided by CCCD is to characterize drug response indicators of tumors by quantitatively|
|measuring the appropriate biomarkers in tumor cells/tumor tissues or circulating cancer cells of the patients. The validated |
|technology is ready for clinical trials. CCCD plans to enter a partnership with hospitals, institutions or companies in clinical|
|trials followed by commercialization of this patented protected technology and service. |
[pic]
|ChanTest Inc. |Arthur Brown |
|Cleveland, OH |Tel: 216-332-1665 |
| |Email: abrown@ |
| |
|ChanTest has offered drug safety testing and discovery services to biopharma since 1998. The company has grown from 2 to 35 |
|employees, has annual revenues of about $6MM and has always been profitable. ChanTest has a reputation for providing expertise, |
|accuracy and urgency to its customers. The company is especially expert in the area of ion channels. ChanTest services include |
|proprietary high throughput assays of ion channel function and trafficking and expression of surface membrane proteins in |
|general. Other services include automated patch clamp, GLP in vitro assays and a growing library of cell lines expressing |
|important ion channels. A proprietary antiarrhythmic drug was discovered serendipitously. The drug is safe in man and a Phase 2 |
|proof of concept clinical trial received support in a pre-IND meeting at FDA. |
[pic]
|Chemica Technologies, LLC |Takuji Tsukamoto |
|Bend, OR |Tel: 541-385-0355 |
| |Email: taku@ |
| |
|Chemica Technologies, LLC is a research-oriented, biotech company. Our mission is to develop medical and pharmaceutical products|
|and therapies that significantly improve and enhance the health and quality of life for people world-wide. Chemica is engaged |
|in both private and Federal fund-based research built on our expertise in biochemistry, chemistry, chemical engineering, and |
|microbiology. The technologies developed through our research efforts are licensed to strategic partners and investors both |
|nationally and internationally. |
[pic]
|Ciencia, Inc. |Salvador Fernandez |
|East Hartford, CT |Tel: 860-528-9737 |
| |Email: fernandez@ |
| |
|Ciencia, Inc. has developed advanced plasmonics biodetection technology for real-time, label-free, highly multiplexed bioassays |
|in microliter volumes. This technology comprises an instrument, and disposable microarray chips. Detection of pathogens and |
|proteins in serum, and assessment of immune cell phenotype and function in bodily fluids have been demonstrated. Applications |
|include biodefense and immune profiling for diagnosis and assessment of autoimmune, infectious and neoplastic diseases. Ciencia|
|is a privately held corporation that develops optical sensors and analytical instruments for biodefense, clinical diagnostics, |
|research, process analysis, environmental monitoring, food safety and forensic/security applications. The Company is seeking |
|partners to form R&D joint ventures with an option to license the technology. |
[pic]
|Clever Sys. Inc. |Yiqing Liang |
|Reston, VA |Tel: 703-787-6946 |
| |Email: yqliang@ |
| |
|Clever Sys. Inc. (CSI) develops and delivers software and systems for automated behavior analysis in life science. CSI’s |
|patent-protected, technology solutions of next generation use intelligent digital video techniques to monitor and analyze lab |
|animal behaviors, provide more new critical and reliable data for scientific research in brain disease, drug discovery, genetic |
|phenotyping, and save huge amount of labor. Our current and potential customers include pharmaceutical companies, biotech |
|companies, and medical and biological research institutes. CSI’s current focus is on complex lab animal behaviors, though its |
|technologies can be applied in patient diagnosis, monitoring and rehabilitation, homeland security, market survey, athletes |
|performance analysis. |
[pic]
|CogniTech Corporation |Jerome Soller |
|Salt Lake City, UT |Tel: 801-322-0101 |
| |Email: soller@cognitech- |
| |
|CogniTech Corporation develops, markets, and sells customized software solutions for data collection, content management, |
|decision support, simulation, and training. These technologies are applied to a variety of domains, including emergency |
|response, homeland security, risk assessment, healthcare information systems, clinical trials, and scientific research. |
|CogniTech Corporation has internationally recognized expertise in many domains, including healthcare informatics, occupational |
|and environmental health, computational chemistry, artificial intelligence, sensor simulation, and e-learning technologies. |
[pic]
|Communication Disorders Technology, Inc. |Charles Watson |
|Bloomington, IN |Tel: 812-336-1766 |
| |Email: watson@ |
| |
|Communication Disorders Technology, Inc.(CDT), founded in 1989, has the goal of becoming the market leader in the development of|
|computer-based technologies for speech and hearing professionals (speech pathologists, audiologists, and teachers of the deaf), |
|teachers of foreign languages and of persons with developmental disabilities. Since its beginning CDT has developed speech |
|production and perception testing and training systems that combine speech-recognition technology with state-of-the-art computer|
|graphics. These systems significantly increase clinical effectiveness and efficiency. CDT’s internationally recognized team of|
|investigators has expertise in speech and hearing sciences, psychology, mathematics, engineering, linguistics, graphical arts, |
|and computer programming. |
[pic]
|Conversion Energy Enterprises |Barbara Soltz |
|Spring Valley, NY |Tel: 845-425-9170 |
| |Email: barbara@ |
| |
|Conversion Energy Enterprises (CEE) is developing laser assisted tissue welding systems which consist of miniature lasers, |
|surgical handpieces and light activated bioadhesives for repairing wounds, closing surgical incisions, fixing implants and |
|grafts. These systems will replace sutures and staples for many surgical applications especially where the surgery is complex |
|or when minimally invasive techniques are required. The benefits of tissue welding include the reduction in tissue trauma and |
|infection, increased closure speed, improved healing response and eliminates detrimental effects of wound leakage. CEE's |
|systems will have widespread use in herniorrhapy, ophthalmic, orthopedic, urinary and gynecological applications. |
[pic]
|Core Tech Solutions, Inc.. |Kirti Valia |
|East Windsor, NJ |Tel: 609-443-1400 |
| |Email: coretech@ |
| |
|Core Tech Solutions, Inc. is a Research, Development and manufacturing company dedicated to the science of transdermal (TDS), |
|topical and buccal delivery systems. The company is developing transdermal patches based on proprietary membrane-controlled |
|technology and drug-in-adhesive technology. Core Tech has developed patches for pain management and hypertension. The company |
|has applied patents for its transdermal products. The company is seeking partners for its Fentanyl-TDS and Clonidine-TDS |
|products. The company’s facilities include R&D laboratory in Mount Laurel, NJ and cGMP manufacturing facility in East Windsor, |
|NJ. The facility is built in compliance with the FDA and DEA requirements. |
[pic]
|Creative Action LLC |Ronni Sterns |
|Akron, OH |Tel: 330-867-9978 |
| |Email: RSterns@ |
| |
|Creative Action LLC develops and delivers innovative solutions for the Age 55+ Market. Products targeted to the institutional |
|market improve the quality of life for older adults in long term care facilities and adult day care centers, while improving |
|staff effectiveness, efficiency and job satisfaction. Based on proven behavioral interventions, therapeutic solutions increase |
|engagement and social interaction among people with cognitive impairments; other solutions enable older adults and staff who do |
|not share a common language to communicate with each other. Products targeted to community dwelling older adults maintain |
|independence by improving medication adherence and functioning for successful completion of daily activities. |
[pic]
|customKYnetics, Inc. |Eric Hartman |
|Versailles, KY |Tel: 859-879-3718 |
| |Email: hartman@ |
| |
|customKYnetics, Inc. is developing exercise and motor retraining devices for use by individuals with neuromotor disabilities |
|secondary to spinal cord injury or stroke. Several of customKYnetics’ potential product offerings utilize neuromuscular |
|electrical stimulation (NMES) for the purposes of exercising paralyzed muscles and generating exercise movements that load bones|
|and joints of the lower extremities. customKYnetics is additionally developing derivative devices which utilize biofeedback |
|with or without NMES to assist clients in regaining voluntary control of paralyzed muscles. |
[pic]
|Cyber Access Systems |Don Forest |
|Bryn Mawr, PA |Tel: 610-527-6391 |
| |Email: donforest@ |
| |
|Cyber Access Systems® (Cyber) has developed a patented, user interface allowing individuals with severe cerebral palsy (CP) or |
|traumatic brain injury (TBI), including those with quadriplegia, to access a computer. Cyber will produce two products: (a) a |
|microcomputer-based voice output system, called CyberSpeech®, targeted to persons whose speech is impaired due to CP or TBI, and|
|(b) add-on software to the CyberSpeech® system enabling persons with CP or TBI who are unable to access a computer via a |
|keyboard or mouse to use Windows application programs. To meet the mobility needs of the same population, Cyber will license |
|its user interface technology to manufacturers of power wheelchairs, enabling severely disabled users to move independently. |
[pic]
|Cytograft Tissue Engineering |Todd McAllister |
|Novato, CA |Tel: 415-506-0240 |
| |Email: todd@ |
| |
|CTE produces tissue engineered blood vessels comprised entirely of the patient’s own cells. The Company’s Lifeline™ vascular |
|graft is targeted at four revascularization indications: hemodialysis patients, lower limb amputation candidates, pediatric |
|patients with congenital defects (cardiac) and coronary bypass candidates. Unlike previous technologies, the Lifeline™ graft |
|does not rely upon synthetic scaffolds or exogenous biomaterials to provide requisite strength. The vessel is fully |
|endothelialized, and is a living tissue with an inherent capacity to grow/remodel. The Lifeline™ graft is currently in Phase |
|I/II clinical trials and is the first completely biological tissue engineered vascular graft to be used in man. |
[pic]
|Detroit R&D, Inc. |Hyesook Kim |
|Detroit, MI |Tel: 313-961-1606 |
| |Email: hskim@ |
| |
|Detroit R&D develops ELISAs for new drug development and assay kits for toxicity screening of drug candidates. Cause of 90% of |
|hypertension is not known. Thus NON-specific hypertension drugs such as beta blocker, calcium channel blocker and ACE |
|inhibitors induces fatigue, dizziness, depression or birth defect. |
|The Company’s patented Hypertension ELISA kit is based on new finding that increased activity of ONE enzyme is responsible for |
|hypertension. Clinical data obtained with the Hypertension ELISA revealed that hypertensive urine specimens were significantly |
|different (98% confidence) from normal specimens. New generation hypertension drugs can be developed using the Hypertension |
|ELISA. |
[pic]
|DIApedia |Martin Bradley |
|State College, PA |Tel: 814-234-0700 |
| |Email: mbradley@ |
| |
|DIApedia is a State College, Pennsylvania company developing new products for the treatment and prevention of diabetic foot |
|ulcers. To date, we have received $4.2M of NIH SBIR funding to support development of three technologies: 1) CAD-CAM footwear |
|for diabetic patients; 2) a 3-D Haptic Lens used to create a digital image of the plantar surface of the patient’s foot; and 3) |
|a Load Relieving Dressing system for healing diabetic foot ulcers. |
[pic]
|Discovery Genomics, Inc. |John Haaland |
|Minneapolis, MN |Tel: 847-491-3279 |
| |Email: johnh@ |
| |
|Discovery Genomics, Inc. (DGI) utilizes a patented, non-viral gene therapy technology, called the Sleeping Beauty Transposon |
|System, to safely and effectively transfer a gene into the chromosome of the cell, allowing for long-term, stable expression of |
|the correct protein. To demonstrate this technology in humans, DGI will sponsor clinical trials at the University of Minnesota |
|Hospital to treat Fanconi Anemia (FA), a rare and fatal blood disease. Validation of DGI’s proprietary technology is expected |
|to lead to cures for other genetically based diseases including Hemophilia A & B, and long-lasting treatments for glioblastoma |
|and breast cancer. |
[pic]
|Eagle Vision Pharmaceutical Corp |Phillip Harnish |
|Exton, PA |Tel: 610-363-6928 |
| |Email: mail@ |
| |
|Eagle Vision Pharmaceutical Corp. is a private development stage company with programs building upon special expertise in the |
|field of injectable imaging agents. Covered by issued and pending patents, the Company’s product candidates enhance Magnetic |
|Resonance Imaging's (MRI) powerful potential to revolutionize the diagnosis and management of heart disease, liver disease and |
|cancer, replacing the more limited, costly and invasive procedures currently used. SeeMore™ (EVP 1001-1) represents a |
|significant commercial opportunity as the only intracellular heart agent that is not radioactive. Phase II studies in heart |
|patients are ongoing to demonstrate the superior diagnostic features of SeeMore™ enhanced MRI. |
[pic]
|Engineering Arts |Peter Wiktor |
|Mercer Island, WA |Tel: 206-275-4221 |
| |Email: wiktor@engineering- |
| |
|Engineering Arts is a technology development and manufacturing company currently specializing in piezoelectric `ink-jet' fluid |
|dispensing technology. Current products include the ActivePipette piezoelectric microfluidic dispensers, the DE02 |
|SignalGenerator to drive the dispensers and a robotic laboratory automation instrument capable of transferring (pipetting) |
|sub-nanoliter fluid samples with micron positioning accuracy. Engineering Arts’ dispensers are used commercially to generate |
|gene expression microarrays. In collaboration with the Fred Hutchinson Cancer Research Center, Engineering Arts is developing a |
|cell-based RNAi microarray assay. Engineering Arts is seeking collaborators to develop other applications that could benefit |
|from microfluidic dispensing and laboratory automation technology. |
[pic]
|FEO Medical, Inc. |Roy Williams |
|Collierville, TN |Tel: 901-853-2244 |
| |Email: rewillia@midsouth. |
| |
|FEO Medical, Inc., located in West Tennessee, offers our clients a broad range of R&D services including: mechanical, |
|electronic, optical, software, and systems design; prototype construction and manufacturing interface; and intellectual property|
|assistance via our in-house Patent Agent. We specialize in LabView and are National Instruments’ Alliance Members. We have |
|worked with a broad range of clients and technologies. Government-sponsored projects include multiaperture vision tracking |
|systems and multi-spectral imaging systems. Products for commercialization include: deep-UV laser delivery and imaging systems;|
|sleep apnea analysis software; visible lightguide illumination systems; and vacuum-based leak detection systems. |
|University-based projects include carbon-dating analysis systems. |
[pic]
|Fermalogic, Inc. |Roy Wesley |
|Chicago, IL |Tel: 312-738-0050 |
| |Email: roy.wesley@ |
| |
|Founded in 1991, Fermalogic is a research-driven biotechnology company that develops and implements strain improvement |
|technology for fermentation-based products to lower the cost of drugs and improve the profitability of pharmaceutical |
|manufacturing. The company's research focus is in industrial microbiology as it applies to strain and process improvement for |
|the production of antibiotics and other natural products. |
|Fermalogic's goal is to bring new technology to the pharmaceutical industry to solve real-world problems in drug production. In |
|response to the never-ending challenge to increase fermentation yield, Fermalogic has developed a strain improvement process |
|based on its patent-pending FermaChannelingSM metabolic engineering technology. |
[pic]
|FM Technologies, Inc. |Vadim Jabotinski |
|Chantilly, VA |Tel: 703-818-9400 |
| |Email: vjabotinski@fm- |
| |
|FM Technologies (FMT) develops technology and instrumentation in the area of high-energy, plasma physics and materials |
|processing for industrial, medical, defense, and environmental applications. The company’s expertise covers particle |
|accelerators, electron guns, ion beam sources, cathodes, particle beam optics, precision measurements and control and power |
|electronics, vacuum systems, microwave heat and radiation treatment of polymers, metals, ceramics, and composite materials. |
|Products for commercialization include: High-brightness penning source of continuous ion beams of O-, H-, Ar+ for biological |
|applications, Microwave joining of ceramics to similar and dissimilar materials, and Electron beam process for prevention of |
|vacuum breakdown in high voltage vacuum devices. |
[pic]
|Frontier Scientific, Inc. |Bert Israelsen |
|Logan, UT |Tel: 435-753-1901 |
| |Email: bvi@ |
| |
|Frontier Scientific, Inc. (FSI) has developed a drug for iron overload treatment. Hereditary hemochromatosis (HH), also known |
|as iron overload disease or "genetic iron poisoning", is the most common genetic disease in the U.S.A. according to the U.S. |
|Centers for Disease Control and Prevention (CDC). 1 in 8 are "silent carriers" of the single HH gene mutation and 1 in 100-200 |
|have the double mutation, putting them at high risk for developing full blown HH. HH can affect men, women and children at any |
|age. Currently, individuals with iron overload diseases have phlebotomy treatments, or the removal of a full unit of blood from|
|the patient, conducted in a medical setting one to two times a week. Now, with the drug under development by FSI, an oral dosage|
|prior to a meal will inhibit iron uptake, allowing people to lead a normal life style and save thousands of dollars in medical |
|expenses each year. |
[pic]
|GeneGo Inc. |Sean Ekins |
|St Joseph, MI |Tel: 269-930-0974 |
| |Email: sean@ |
| |
|GeneGo develops tools for the integration and systems level analysis of high-throughput experimental data in human biology and |
|medicinal chemistry. Our flagship product, MetaCore™, assists scientists in drug target selection, validation, and |
|identification of molecular biomarkers. MetaCore™ is an integrated analytical suite with data parsers, visualization tools and |
|flexible network building algorithms. MetaCore works with the proprietary content of MetaBase™ our manually curated database of |
|human biology which allows one to network over 90% of the known human proteins via direct interactions. Our second product, |
|MetaDrug™, deals with prediction of human metabolism and toxicity of novel small molecules and compounds. |
[pic]
|General BioTechnology, LLC |Erik Woods |
|Indianapolis, IN |Tel: 317-917-3450 |
| |Email: erik@ |
| |
|General BioTechnology (GBT) is a cell processing company based on novel technologies including methods and devices specifically |
|related to giving biological cells and tissues shelf life. The company has made advancements to improve cryopreservation and |
|banking methods for such diverse cell and tissue types as human pancreatic islets of Langerhans, blood platelets, umbilical cord|
|blood, peripheral blood stem cells and spermatozoa. Presently, GBT also runs a commercial cord blood bank and anonymous donor |
|and autologous sperm bank. GBT is registered with the FDA as an HCT/Ps facility and is licensed by the State of Indiana as a |
|Clinical Blood Center Program. |
[pic]
|Genex Technologies, Inc. |Matthew Durbin |
|Kensington, MD |Tel: 301-962-6565 |
| |Email: matthew.durbin@ |
| |
|Founded in 1995, Genex Technologies is a world leader in 3D Imaging, 3D facial recognition, and intelligent surveillance. |
|Genex’s highly accomplished staff of engineers and project managers deliver practical solutions to some of today’s most |
|challenging imaging needs. With internal expertise in fields ranging from optics to mechanical design to electronics, Genex’s |
|innovative team solves complex problems every day. |
|Genex offers solutions and design competencies in the following areas: |
|High-Speed 3D Capture |
|3D Editing and Post-Processing |
|3D Data Manipulation |
|3D Display The Intelligent |
|Optical Design |
|High-Speed Image Processing |
|Algorithm Development |
|Remote, Unmanned Applications |
|WatchList |
|Access Control |
|Composite Sketching |
[pic]
|GLSynthesis Inc. |George Wright |
|Worcester, MA |Tel: 508-754-6700 |
| |Email: george.wright@ |
| |
|GLSynthesis is a 9-year old, private company that performs laboratory scale (custom) organic synthesis, drug discovery research,|
|and chemical product manufacturing. Customers include major US and international pharmaceutical companies, startup drug |
|discovery and "virtual" companies, biotechnology companies, suppliers of fine chemicals, nutriceutical companies, and academic |
|and research institutions. Drug discovery, including in vitro and in vivo pharmacology and pharmacokinetics, is accomplished |
|through corporate contracts and small business (NIH) grants. We have developed the Fluorosome Technique for drug absorption and |
|disposition studies, and are actively marketing it. We develop, market, and sell several specialty chemicals worldwide, produced|
|directly by our affiliate company Shanghai GLSynthesis, Shanghai, China. |
[pic]
|Goldfinch Diagnostics Inc. |Louis Kirchhoff |
|Iowa City, IA |Tel: 319-335-6786 |
| |Email: louis-kirchhoff@uiowa.edu |
| |
|Goldfinch Diagnostics Inc. was founded in 1997 with the goal of developing diagnostic assays for infectious diseases. To date |
|its activities have been focused on the development of hybrid recombinant antigens useful for the diagnosis of Chagas disease. |
|The primary support for these activities has been a SBIR grant from the NIH. |
[pic]
|Gwathmey, Inc. |Judith Gwathmey |
|Cambridge, MA |Tel: 617-491-0022 |
| |Email: jgwathmey@ |
| |
|Gwathmey, Inc. the “The Thinking Pre-Clinical Contract Research Organization” TM provides both GLP and non-GLP studies for in |
|vivo and in vitro drug screening for lead compounds, pharmacokinetic, toxicology, biodistribution studies and efficacy testing |
|in animal models. We work in the Arthritis, Cancer, Cardiovascular, CNS, Infectious Disease, Diabetes and Obesity therapeutic |
|areas. Our world-class scientists and state-of-the-art research facilities are used to conduct proof-of-concept and key |
|experiments for FDA drug approval. We significantly change the risk-reward profile and effectively bridge the difficult gap |
|between chemistry and biology. Our goal is to conduct efficient, physiologically sound studies in order to provide high quality |
|data for quality drug development decision making. |
[pic]
|HemoGenix, Inc |Ivan N. Rich |
|Colorado Springs, CO |Tel: 719-264-6250 |
| |Email: ivannrich@ |
| |
|HemoGenix specializes in developing and producing sensitive in vitro luminescence proliferation assays to meet the need in 3 |
|market areas. These include detecting and predicting hemotoxicity during drug discovery and development, multifunctional |
|research assays for basic research and quality control in stem cell transplantation and cord blood storage processing |
|laboratories. The HALOTM Platform, fulfils all 3 arenas as both a contract service and a product line of over 400 assay kit |
|variations. HemoGenix provides these services and kits worldwide. HALOTM and its applications is one of 4 luminescence assay |
|products within the HemoGenix intellectual property portfolio. |
[pic]
|IA, Inc. / ThreeFold Sensors |Judith Erb |
|Ann Arbor, MI |Tel: 734-995-9338 |
| |Email: jerb@ |
| |
|ThreeFold Sensors, Inc. (TFS) develops and markets portable biosensor instruments and a variety of sensor cartridges having |
|applications in medical diagnostics and environmental testing. Our sensors provide, in 3 minutes, results of comparable |
|sensitivity to those obtained by immunoassays requiring 4-24 hours. The technology has been developed through $7.5 million in |
|SBIR grants and is protected by seven pending patents. Our instrument's small size brings reference lab quality tests to field |
|testing and point of care settings. Our panel of rapid reproductive hormone tests will be introduced to fertility clinics in |
|2006. Sensors for assessing which pharmaceuticals will best treat an individual's cancer are in development. |
[pic]
|IBET, Inc. |Eric Plum |
|Columbus, OH |Tel: 614-487-1379 |
| |Email: eplum@ |
| |
|IBET Inc.’s corporate focus is on research and development of instrumentation for the biochemical, biophysical, and biomedical |
|sciences. The company’s expertise and experience in biothermodynamics has inspired development of proprietary technology for |
|monitoring thermal and thermodynamic properties of macromolecules; specifically, temperature-dependent UV/Vis spectroscopy and |
|ultrasonic velocimetry. IBET Inc. has developed analytical instruments designed to provide new and unique information about the|
|thermodynamic properties of biologically important macromolecules and biomolecular interactions. These instruments address a |
|deficiency in high-throughput thermodynamic methods resulting from the explosive growth in knowledge of DNA and protein sequence|
|information. |
[pic]
|Ichor Medical Systems, Inc. |Robert Bernard |
|San Diego, CA |Tel: 858-550-2022 |
| |Email: rbernard@ |
| |
|Ichor Medical Systems has developed a powerful, patented electroporation technology for delivery of DNA drugs. Although |
|electroporation is a broadly utilized method for DNA drug delivery in various animal models, commercialization of this |
|technology has been hindered by the lack of a reliable and clinically acceptable means for human administration. Ichor’s |
|proprietary TriGrid™ Delivery System integrates several patented electroporation technologies into a simple handheld clinical |
|device that enables safe, efficient and reproducible DNA administration with minimal clinical training. This powerful |
|technology delivers on the promise of DNA drugs and vaccines, addressing the significant unmet medical needs of numerous |
|debilitating and life threatening diseases. |
[pic]
|INCELL Corporaton, LLC |Mary Pat Moyer |
|San Antonio, TX |Tel: 210-877-0100 |
| |Email: mpmoyer@ |
| |
|INCELL has developed innovative and patented platform technologies for non-needle vaccine delivery and intends to make an impact|
|on global health by changing the vaccine delivery paradigm. Its oral and nasal smallpox vaccines will complete Phase I/II |
|clinical trials by Q3 2006 and provide supportive technology information to influenza, HIV and other vaccines in development. |
|INCELL manufactures and sells products to biotechnology and pharmaceutical markets, and provides contract research services |
|relevant to pre-clinical and clinical products for infectious disease, regenerative medicine, stem cells, chem-bio defense, and |
|cancer. INCELL has a strong multi-product pipeline, including a cancer nutraceutical in clinical trials. |
[pic]
|INFOTECH Soft, Inc |Mansur Kabuka |
|Miami, FL |Tel: 305-670-5111 |
| |Email: kabuka@ |
| |
|INFOTECH Soft, Inc. specializes in the application of XML and Web technologies to create next-generation software solutions for |
|health and life sciences research. INFOTECHSoft’s ASPECT clinical trial management system combines intelligent electronic form |
|and trial models designed around XML Schema, which contain instructions for sophisticated data verification, automated |
|calculation, and conditional processing. The system can be deployed in single location studies or large, multi-center clinical |
|trials communicating over Internet connections. It increases data accuracy and enables timely protocol compliance monitoring, |
|reducing the overall costs of executing a clinical trial and the total time-to-market of promising drugs or therapies. |
[pic]
|Inframat Corporation |Zongtao Zhang |
|Willington, CT |Tel: 847-491-3277 |
| |Email: zzhang@ |
| |
|Inframat® is a global leader in the development and commercial sale of powder and solution feedstocks for thermal sprayed |
|industrial nanocoatings and currently holds over one dozen nanocoatings patents (U.S. and foreign). Inframat's ceramic |
|nanocoating product, NanoxTM 2613 Thermal Spray Feedstock, which received an R&D100 Award in 2001, has been in use on shipboard |
|(propeller shafts) for several years and is currently is "spec’d" and blueprinted with the U.S. Navy. Inframat® has applied |
|similar nanocoatings to medical applications, and has licensed this patented technology to a major orthopedics company. |
|Inframat® Advanced Materials, a commercial subsidiary, sells nanomaterials throughout the world. |
[pic]
|Integrative BioInformatics, Inc. |Ann Chasson |
|Los Altos, CA |Tel: 650-906-4876 |
| |Email:chasson@ |
| |
|Integrative Bioinformatics is a scientific software and consulting services company with expertise in the modeling and analysis |
|of biological systems. Our software product, ProcessDB, helps molecular cell biologists, physiologists and pharmacologists |
|manage and test their increasingly complex mechanistic hypotheses. ProcessDB does this with a powerful but biologically |
|intuitive graphical user interface that helps biomedical researchers formulate, visualize and test their theories of cellular |
|and physiological function. ProcessDB allows investigators to know what their theories predict for any collection of |
|experimental designs, and it speeds discovery of mechanisms that account for all of the available experimental data. By |
|leveraging database, kinetic modeling, and visualization technologies, ProcessDB supports knowledge management for research |
|organizations working on complex biological problems. |
[pic]
|Intrinsic Bioprobes, Inc. |Randall Nelson |
|Tempe, AZ |Tel: 480-804-1778 |
| |Email: rnelson@ |
| |
|IBI’s mission is to improve the diagnosis and treatment of disease through the application of novel proteomics technologies and |
|findings”. |
|IBI’s proprietary technologies are used in the study of diseases for biomarkers discovery/validation and subsequent diagnostic |
|application. Presently, IBI operates in the proteomics instrumentation, services and intellectual property markets, with |
|respective offerings of MASSAY® analytical systems, contract research programs and licensing arrangements. |
[pic]
|Ionwerks, Inc |Ketti Eipers-Smith |
|Houston, TX |Tel: 713-522-9880 |
| |Email: kes@ |
| |
|Ionwerks, Inc. designs and manufactures a complete line of instrumentation and electronics for Time-of-Flight (TOF) mass |
|spectrometry. Our patented instrument couples ion-mobility (IM) of MALDI desorbed ions with orthogonal time of flight (oTOF) |
|mass spectrometry to provide analysis of small molecules unidentifiable by MALDI alone, such as drugs of abuse, lipids, and |
|neuropeptides. Ionwerks’ revolutionary technology can simultaneously separate and identify low mass ions while analyzing larger|
|mass ions from intact molecules and biomolecules. In addition to important biological and clinical applications, the generalized|
|techniques and instrumentation are applicable to numerous other fields, including materials analysis and environmental sampling.|
[pic]
|Kinetic Muscles, Inc. |Ed Koeneman |
|Tempe, AZ |Tel: 480-557-0448 |
| |Email: ekoeneman@ |
| |
|Kinetic Muscles, Inc. products help people with neurological disease such as stroke to improve the use of their hands, arms and |
|legs. We make the first and only multi-modal active-motion device for home and clinic based therapy of neuromuscular |
|disability. Says one user, "Regaining my grip has changed my outlook on getting my life back." KMI is poised to accelerate |
|from the current convergence of neuroscience advances, a home healthcare trend and its early foothold in the neurotherapy |
|market. Its products are an important, cost-effective solution that improves the quality of life for millions of people. The |
|accomplishments and experience of its team have demonstrated a path toward success. |
[pic]
|Kumetrix, Inc |Wilson Smart |
|Union City, CA |Tel: 510-476-0950 |
| |Email: smart@ |
| |
|Kumetrix has developed a unique medical diagnostics technology based on bioMEMS (Micro-Electro-Mechanical Systems). A |
|single-use disposable silicon microchip, with integrated hollow microneedle comparable in size to a human hair, punctures the |
|skin, draws a sub-microliter blood sample into the body of the chip, and performs a specific assay without subsequent blood |
|transfer. The chip mates with the actuator of a handheld meter, which automatically performs the puncture under microprocessor |
|control, reads the assay, displays the result, and stores it in memory. This single-step method renders blood testing painless,|
|rapid, clean, and inexpensive, while requiring no skill from the operator. |
[pic]
|Leo Lens Technology |Praful Doshi |
|San Diego, CA |Tel: 858-335-2873 |
| |Email: prafdoshi@ |
| |
|Leo Lens Technology, Inc. has developed the next generation product for the lucrative $4 Billion contact lens industry. With |
|the Leo Lens technology, exact coloring and iris imaging can now be achieved creating a superior product for the cosmetic and |
|prosthetic segment. This globally patented and FDA approved technology is ready for manufacturing scale-up. Leo Lens is looking|
|for both strategic and financial partners to fully commercialize this innovative product. |
[pic]
|LIFETECHniques, Inc. |Karen West |
|Santa Barbara, CA |Tel: 561-317-8106 |
| |Email: karen@ |
| |
|MedSignals™ is a product line of communicating medication devices to aid adherence. The smart pillboxes alert at pill times, |
|time-stamp usage with each lid opening, upload data to servers daily, and post usage times on charts for authorized caregivers. |
|As a data collection tool, MedSignals imports easily to spreadsheets. A handheld MedSignals pillbox showed significantly |
|improved compliance in one NIAID-funded study. Other models in development include a wireless model for chronically ill children|
|with a GPS locator. MedSignals will introduce its first commercial model in August, 2006. It will sell through insurance plans, |
|trade shows, medical supply companies and pharmacies. |
[pic]
|Lohocla Research Corporation |Boris Tabakoff |
|Denver, CO |Tel: 303-724-3668 |
| |Email: boris.tabakoff@uchsc.edu |
| |
|Lohocla is a preclinical-stage company focused on the therapy and diagnosis of pain, psychiatric and addictive disorders. The |
|lead product, DCUK, is a patent protected, novel compound that has demonstrated biological activity in animals for pain, |
|anxiety, and alcohol dependence. The lead indication is severe chronic pain. The pain management market is over $32 billion in|
|the USA, and current medications are suboptimal. To date DCUK has been shown to be safe, and to have significant activity for |
|severe pain. Lohocla is currently conducting preclinical FDA studies to pursue potential indications for phantom limb pain, |
|cancer pain, and dental pain. |
[pic]
|Lucid Inc. |Jay Eastman |
|Rochester, NY |Tel: 585-239-9800 |
| |Email: jme@lucid- |
| |
|Business Description: Lucid, Inc. is a medical device and information company that has developed, patented, and produced |
|confocal microscopes (trademarked as VivaScopes®) that produce images of living cells for real-time medical imaging and |
|diagnosis in a doctor’s office. VivaScopes®, when coupled with Lucid’s patented digital pathology PACS system, allows real-time|
|diagnosis of many malignant diseases - without the need for invasive biopsy. Lucid intends to launch its products for |
|dermatologic surgery followed by screening of skin cancers. Ultimately the technology can be applied in many other areas of |
|diagnostic and surgical pathology. Lucid’s business model derives revenues from device sales and from transaction fees for its |
|digital pathology PACS services. As the installed base of VivaScopes® grows, Lucid will derive the majority of its revenues from|
|transaction fees. |
[pic]
|Lynntech, Inc. |Scott McKenzie |
|College Station, TX |Tel: 979-693-0017 |
| |Email: scott.mckenzie@ |
| |
|Lynntech is an "innovation engine", applying in-depth experience in research, technology development, prototyping, and product |
|commercialization. We perform research and development for a variety of clients (leading corporations, Federal R&D and venture |
|capital) helping them meet their strategic goals under the ever-increasing pressures of faster technology cycles and heightened |
|competition. Our advanced life sciences chemistries and devices business strategy focuses on creation of value for early and |
|prototype stage inventions and intellectual property derived internally and/or in partnership with leading university faculty |
|inventors. Lynntech growth is achieved through partnerships offering cutting-edge technologies for licensing, and through the |
|creation of investment opportunities in new ventures. |
[pic]
|Maine Molecular Quality Controls, Inc. |Joan Gordon |
|Scarborough, ME |Tel: 207-885-1072 |
| |Email: jgordon@ |
| |
|Maine Molecular Quality Controls, Inc. (MMQCI) provides the biomedical industry with innovative, high-quality control products |
|for molecular diagnostics. MMQCI products fulfill Federal regulations by monitoring the entire molecular laboratory test, |
|including extraction. Products are composed of synthetic nucleic acid constructs stabilized by a unique proprietary matrix. All |
|are uniquely designed to be analyzed as natural biological samples. Unlike biologicals, MMQCI controls contain multiple |
|mutations in single samples. This key feature renders the controls comprehensive and cost efficient, allowing more complete |
|quality assurance. Products are non-infectious, facilitate documentation requirements and provide consistent results to aid the |
|identification of potential system problems. |
[pic]
|Maxwell Sensors Inc |Winston Ho |
|Santa Fe Springs, CA |Tel: 562-801-2088 |
| |Email: winstonho@ |
| |
|Maxwell Sensors Inc has developed a proprietary microfluidic bio-disc technology. The microfluidic chemiluminescence |
|(MCL)-bio-disc products offer multiplexed assays, rapid test results, and significantly more sensitivity (100 - 1,000 times) and|
|accuracy than the current Point of Care Testing systems. The technology provides “low cost”, "miniaturization", "integration", |
|and "total automation" for a wide variety of immunoassay and molecular diagnostic applications. Cardiac markers and infectious |
|diseases panel tests are our initial market applications. |
[pic]
|Microwave Imaging System Technologies |David DeLucia |
|Norwich, VT |Tel: 802-649-8109 |
| |Email: delucia@ |
| |
|MIST Inc. is an early stage medical device company which has demonstrated an improved system for breast cancer screening and |
|diagnosis. The addressable market is 40 million women in the US ($4B/yr in screening service from >$1B of capital equipment). |
|The worldwide market is four times larger. |
|In human clinical testing of >150 patients at the Dartmouth-Hitchcock Medical Center we have demonstrated performance equivalent|
|to an MRI at one tenth the cost. This success reflects over $6M invested by the National Institute of Health in developing our |
|technology. |
|Intellectual property is issued and wholly owned. |
[pic]
|Molecular LogiX, Inc |Daniel Monticello |
|The Woodlands, TX |Tel: 847-491-3284 |
| |Email: dmonticello@ |
| |
|'Molecular LogiX is a drug discovery company. The Company is developing a new class of protein-based therapeutics to treat |
|cancer. Our initial focus is on developing Anti-Cancer Ligands (ACL) directed against Receptor Tyrosine Kinases (RTK) implicated|
|in cancer. We have developed a potent new “Pan-HER” ACL that has the potential to be a valuable new weapon in the fight against |
|cancer. This “First in Class” compound reflects an entirely new approach to interfering with the RTK-dependent progression of |
|disease. The Company’s business strategy is to develop the drug leads it creates through Phase II clinical trials and then |
|partner them with larger biotechnology and pharmaceutical companies. |
[pic]
|Molecular NeuroImaging |Kenneth Marek |
|New Haven, CT |Tel: 203-401-4300 |
| |Email: kmarek@ |
| |
|Molecular NeuroImaging, LLC (MNI) is a neuroimaging services company specializing in the efficient application of scintigraphic |
|biomarkers in drug development and clinical research for neurodegenerative and neuropsychiatric disorders. MNI provides |
|services across the pre-clinical and clinical spectrum including radioligand development, design and implementation of Phase 1 |
|to Phase 4 clinical imaging trials, and customized clinical imaging site coordination and management in multi-site imaging |
|studies. Our strong emphasis is on using investigational radiotracers with quantitative imaging outcome measures as diagnostic |
|tools and/or for assessing disease mechanism or progression. Our focus is on developing radioligands as tools for human |
|research. |
[pic]
|MRPath Incorporated |Robert Lontz |
|Durham, NC |Tel: 919-806-0081*308 |
| |Email: rjlontz@ |
| |
|MRPath, Inc. specializes in the conduct of high performance magnetic resonance imaging (MRI) protocols for accelerating the |
|discovery of new biopharmaceutical targets and evaluation of their safety, and rodent models of disease and toxicity. Our |
|technology enables the study of effects in the same animal over extended times, and three-dimensional imagery of in-context |
|bio-structure with exceptional resolution and field of view. Unlike previous technologies, the company’s technology enables |
|quantitative morphological measurement. MRPath integrates its MRI with complementary imaging technologies into image-centric |
|study report formats, which are available to customers in a web-enabled document and image management system. |
[pic]
|Nanoprobes, Incorporated |Richard Powell |
|Yaphank, NY |Tel: 919-845-6324 |
| |Email: rpowell@ |
| |
|Nanoprobes, Incorporated researches and develops novel technology for the detection and visualization of biological targets |
|using targeted metal nanoparticles and metallographic reactions. The company is developing improved X-ray contrast agents for |
|angiography and vascular imaging which provide enhanced sensitivity, combined with low toxicity and very low viscosity, thus |
|minimizing vascular damage and enabling imaging in organs such as the brain, or in obese patients where current contrast agents |
|are not well tolerated. These reagents are also applicable to the specific imaging of cancer, and high-resolution imaging of |
|smaller blood vessels and features (Micro-CT). |
[pic]
|Neuronautics, Inc. |Sam Khatami |
|Evanston, IL |Tel: 847-491-3271 |
| |Email: skhatami@ |
| |
|Neuronautics, Inc. (“NNI” or the “Company”) was founded in 1997 with the mission to develop diagnostic and therapeutic |
|treatments for the early detection and eventual prevention of Alzheimer’s disease (AD) and other related neurodegenerative |
|disorders. These disorders are characterized by the formation of structures called neurofibrillary tangles (NFTs) from molecules|
|of tau protein that associate into insoluble polymers. The Company believes that drugs that can inhibit or prevent NFT formation|
|will prevent the progression of AD or, given early diagnosis, potentially reverse the course of the disease. In collaboration |
|with leading experts and renowned academic institutions, NNI has discovered several potent anti-tangle drug candidates. |
|Eventually, NNI anticipates partnering with major pharmaceutical companies to take these compounds through the clinical testing |
|necessary to support FDA approval. |
[pic]
|NOCwatch International, Inc. |Kathryn Kelly |
|Crystal Bay, NV |Tel: 775-833-4142 |
| |Email: kek@ |
| |
|Our nation’s elderly fall about 10 million times per year, frequently incurring major disability and significant social and |
|economic costs. NOCwatch has completed two clinical trials resulting in the first device ever shown to reduce falls and |
|injuries in this high-risk population. It does so with a small, inobtrusive patch attached like a band-aid to the patient's |
|thigh that reliably alerts staff or family that a patient is trying to get up unassisted, without sending false alarms. The |
|alarm in the room reminds the patient that they are not to get up unassisted (which works particularly well with dementia |
|patients), and can also be connected to a nurse call system to call a nurse or page a relative. The low-cost, Class I-exempt |
|device is worn for up to three weeks before being disposed of with regular waste, and can be worn while bathing and during |
|x-rays, MRIs, etc. More information can be found at . |
[pic]
|Novarx Corporation |Habib Fakhrai |
|San Diego, CA |Tel: 847-491-3285 |
| |Email: fakhrai@ |
| |
|NovaRx has developed and utilized a technology that has significantly prolonged survival and improved the quality of life in |
|cancer patients. |
|NovaRx is a clinical-stage biopharmaceutical company. It's lead product, Lucanix™, is at the end of a Phase II clinical trial |
|for the treatment of non-small cell lung cancer. Results demonstrate median survivals more than twice that of approved drugs |
|with only minor toxicities. NovaRx is meeting with the FDA in the fourth quarter of 2005 in order to initiate a Phase III |
|clinical trial for Lucanix™ in early 2006. |
| NovaRx hopes its additional technologies under development will transform cancer into a controllable disease such as diabetes. |
[pic]
|Optimer Pharmaceuticals, Inc |Alex Romero |
|San Diego, CA |Tel: 858-909-0736 |
| |Email: aromero@ |
| |
|Optimer Pharmaceuticals, Inc., a privately held San Diego-based company, has two late-stage drugs to treat life-threatening |
|bacterial infections under development |
|and a range of preclinical antibiotics discovered through our powerful carbohydrate drug discovery engine. Optimer's core |
|competence includes the development of innovative drugs for treating diseases that currently have no satisfactory therapy. These|
|include antibiotics for drug-resistant bacterial infections, a cancer vaccine, and "disease-modifying" drugs for |
|osteoarthritis. In the near term Optimer plans to bring in significant revenues through sponsored research, joint ventures, |
|government grants, and license royalties. |
[pic]
|Panomics, Inc. |Jason Li |
|Redwood City, CA |Tel: 650-216-9736 |
| |Email: jasonli@ |
| |
|Panomics, Inc., incorporated in California in September 2000, is a biotechnology-based company dedicating to the development of |
|innovative tools for the functional studies of proteins. Panomics began its official operations on November 2000 and launched |
|its products on July 2001. Since then, the company has been launching more than one thousand products to the market. Panomics |
|has established an international distribution network covering all major countries and is establishing its sales network in |
|North America. Panomics was ranked #4 among 100 fastest-growing companies in San Francisco Bay area by San Francisco Business |
|Times and #6 among 50 fastest-growing private companies in Silicon Valley by San Jose Business Journal in 2004. Panomics has |
|been awarded 7 SBIR/STTR grants of total $2.5M by the National Institutes of Health (NIH). Panomics has become a profit |
|organization since 2003, Panomics acquired in 2003 FreshGene, a small biotech company engaged in the development of SNP |
|detection technologies. Panomics has filed more than 15 patents, 7 of which are issued. Panomics has now 12 full-time |
|employees; 4 of them are PhD/MD scientists, and it occupies a facility with 6,500 square feet of lab and office space in Redwood|
|City, California. Panomics also has a strong scientific consultant team including Michael Rosenfeld, who is the members of |
|National Academy of Sciences. |
[pic]
|Paradigm Pharmaceuticals, LLC |Fatih Uckun |
|St. Paul, MN |Tel: 612-965-4894 |
| |Email: fatih_uckun@ |
| |
|Paradigm Pharmaceuticals, LLC is a start-up, for-profit Minnesota limited liability pharmaceuticals company. The goal of |
|Paradigm Pharmaceuticals is to develop new and active pharmaceuticals for the prevention and treatment of viral infections and |
|malignancies. Paradigm Pharmaceuticals is currently developing bench-to-bedside patent-applied technologies towards final |
|product and approval stages in order to produce the highest quality pharmaceutical and consumer health care products in the |
|world. Complete in house laboratory set-up with state-of-the-art equipment is established. Extensive research studies have been|
|conducted and the most beneficial and extraordinary drug candidates have been tested in animal models to confirm efficacy, |
|potency, and toxicity. |
[pic]
|Perinatronics Medical Systems |Thomas Frank |
|Millersville, MD |Tel: 410-987-1305 |
| |Email: thomasfrank@ |
| |
|Perinatronics develops and clinically tests innovative diagnostic medical instrumentation. In obstetrics, we developed a |
|unique, patented non-invasive fetal heart rate monitor used for advanced antepartum testing and monitoring during labor and |
|delivery. It is the only device available to non-invasively monitor clinically significant fetal heart rate beat-to-beat |
|variability. Recently, our priority has been the development of our innovative patent-pending ECG triggering system to improve |
|cardiac magnetic resonance imaging. This ECG gating system provides for reliable and robust triggering of the moving heart and |
|coronary arteries. We work closely with leading physicians at the University of Maryland School of Medicine, Johns Hopkins |
|Hospital, Barnes Hospital, and the National Institutes of Health Clinical Center. |
[pic]
|Persyst Development Corporation |Scott Wilson |
|Del Mar, CA |Tel: 858-755-4565 |
| |Email: scottw@eeg- |
| |
|Persyst is the world’s largest developer of software for EEG (electroencephalograph) review and analysis. Current markets |
|include clinical review, epilepsy monitoring and diagnosis, and ICU monitoring. Our recently developed AutoLearn™ technology |
|allows patient dependent algorithms to be developed on the fly from EEG and critical care parameters. The EEG technician marks a|
|single example of the pattern of interest and the neural networks are trained instantaneously (< 1 s) without user intervention.|
|New examples can be identified to refine the algorithm without retraining. The same technology allows patient independent |
|algorithms to learn over time. |
[pic]
|Phantoms by Design Inc. |Thomas Burke |
|Bothell, Wa |Tel: 425-481-3515 |
| |Email: tburke@ |
| |
|PBD produces anthropomorphic phantoms of human hearts for use in developing and testing percutaneous interventional devices and |
|procedures such as AF ablation, septal defect closure and valve replacement. The physical models are based on clinical image |
|data and provide a stable, well characterized, clinically relevant environment which reproduces the form and key functionality |
|of native heart tissues. Properly employed, PBD’s models will streamline development cycles, speeding the delivery of |
|interventions in less time with enhanced performance. Though phantoms will never replace animal and human testing, they can |
|reduce the time and expense of animal testing and improve clinical trial outcomes. |
[pic]
|Pharmacon International, Inc. |Renee Arnold |
|New York, NY |Tel: 212-480-4500 |
| |Email: rarnold@ |
| |
|Pharmacon International, Inc. has created a proprietary software program, EB-Health ALERTS©, that manages information to improve|
|health outcomes. EBH ALERTS™ (Evidence-Based Health Automated Live E-Health Response Tracking System) is a fully automated, |
|remote, prospective health and disease monitoring tool, accessible via Internet and interactive voice response, which will (1) |
|facilitate identification of people at greatest risk of developing specific diseases, (2) take steps to intervene early to |
|prevent disease onset and (3) improve management of patients with chronic diseases. The program aims to enhance patient-provider|
|communication through automation and decrease healthcare costs by providing cost-effective deployment of disease management |
|programs. |
[pic]
|PharmaSeq, Inc. |Wlodek Mandecki |
|Monmouth Jct., NJ |Tel: 732-355-0100 |
| |Email: mandecki@ |
| |
|PharmaSeq's provides ultra high-throughput, low-cost, multiplex bioassays and instruments for research and clinical use. The |
|Company has pioneered a unique technology based on an ultra-small silicon integrated circuit, a microtransponder, which, when |
|activated by laser light emits a radio frequency signal carrying a unique identification code. In biological applications, |
|microtransponders are read in a flow-based instrument developed by the Company. The first applications are in detecting genetic|
|abnormalities (mutations, SNPs), such as the cystic fibrosis assay. The Company plans to move forward with applications in |
|other aspects of genomics, proteomics, pharmaceutical drug discovery, and combinatorial chemistry. |
[pic]
|Physical Sciences Inc. |Mark Druy |
|Andover, MA |Tel: 847-491-3272 |
| |Email: druy@ |
| |
|Physical Sciences Inc., a 33 year old company, develops and commercializes advanced technologies for the aerospace, energy, |
|environmental, manufacturing, and medical markets. PSI is currently developing an ultra-sensitive system for direct measurement|
|of singlet oxygen during Photodynamic therapy (PDT). Photodynamic therapy (PDT) is a rapidly developing and extremely promising|
|branch of oncology. FDA approval has been granted for treatment of esophageal and certain lung cancers using PDT. To date, there|
|is no commercially available instrument that can directly measure the real time profiles of singlet oxygen during PDT |
|treatment. Singlet oxygen formation is a key factor in understanding the response of the cancer to PDT. An instrument that can|
|measure real-time profiles will greatly accelerate the ability of PDT to treat various cancers. |
[pic]
|PhysioGenix, Inc. |John Seman |
|Wauwatosa, WI |Tel: 414-431-6600 |
| |Email: john.seman@ |
| |
|PhysioGenix was formed by leading researchers at the Medical College of Wisconsin (MCW) to commercialize the Founders’ vision of|
|reducing drug failures in clinical trials by improving pre-clinical animal models for predictive toxicology, drug screening, and|
|target validation. To fulfill this vision the Company has brought physiology to the genome by engineering multigenic rat models |
|using genetics, genomics, and bioinformatics to match human disease. PhysioGenix uses these animals to provide contract research|
|services related to predictive toxicology and therapeutic proof-of-concept to pharmaceutical companies to help them accelerate |
|their product development processes. |
[pic]
|Pinnacle Technology Inc. |Donna Johnson |
|Lawrence, KS |Tel: 785-832-8866 |
| |Email: donnaj@ |
| |
|Pinnacle develops and commercializes innovative medical devices for animal research. The company targets the pharmaceutical |
|industry, research laboratories and universities that use over 20 million mice and rats each year in the United States. Turnkey|
|Pinnacle systems include biosensors, wireless or tethered data acquisition systems, and software. Pinnacle’s sensors and |
|systems are well suited for high throughput drug screening, and they enable research that will elevate our understanding of the |
|chemical origins of behavior and many disorders including: sleep disorders, heart disease, Parkinsons, and Alzheimers. |
[pic]
|Platypus Technologies |Barbara Israel |
|Madison, WI |Tel: 608-237-1274 |
| |Email: bisrael@ |
| |
|Platypus Technologies is a Bio/Nanotechnology company. We are developing a new generation of diagnostics, monitors and sensors |
|based on the use of nanostructured surfaces and liquid crystals. Platypus technology enables label free detection of proteins, |
|cells, viruses and volatiles. Our products will allow scientists to monitor large scale outbreaks of diseases such as avian |
|influenza using sensitive, rapid assays that permit digital acquisition, analysis and sharing of data and that can be conducted |
|in low technology environments. Platypus technology will also permit the quantitative, individual monitoring of exposure to |
|environmental toxins, such as pesticides. Our products will be useful in basic research, clinical medicine, environmental |
|studies and military applications. Platypus has received over $10 million in competitive SBIR funds to advance the development |
|of this powerful platform technology. |
[pic]
|PortaScience Inc. |Wai Law |
|Moorestown, NJ |Tel: 847-491-3273 |
| |Email: wailaw@ |
| |
|PortaScience Inc. focuses on new product development for point-of-care diagnostic tests which address clinical and consumer |
|markets. The team has experience in commercializing over 50 FDA approved diagnostic products, and has licensed out or |
|commercialized five products in the last five years. |
[pic]
|Praevium Research, Inc. |Vijaysekhar Jayaraman |
|Santa Barbara, CA |Tel: 805-448-4008 |
| |Email: vijay@ |
| |
|Praevium Research, Inc. is a developer of compact semiconductor-based sources of broadband optical radiation for biomedical |
|imaging and other sensor applications. Current development efforts include broadband sources for Optical Coherence Tomography, |
|multi-wavelength laser arrays for diffuse optical spectroscopy, and dense laser clusters for near infrared agricultural |
|spectroscopy. Praevium core technologies include semiconductor wafer bonding, processing, and epitaxial growth, and |
|micropackaging of semiconductor sources. These technologies are being employed to create sources with maximum wavelength |
|coverage in conjunction with minimum size and power dissipation. |
[pic]
|Premitec Inc. |Helmut Eckhardt |
|Raleigh, NC |Tel: 919-424-4456 |
| |Email: eckhardt@ |
| |
|Premitec, Inc. was founded as a spin-off from the Biomedical Microsensor Laboratory and the Center for Advanced Manufacturing |
|Processes and Materials at North Carolina State University in Raleigh. The company uses its expertise in microfabrication |
|technology to provide research, product development and manufacturing expertise to medical device, diagnostics, genomics and |
|drug screening companies. In addition the company is developing proprietary biomedical sensors and implant devices. |
|Premitec’s platform technology combines its microfabriation technology for flex substrates with the proprietary A-coatTM |
|encapsulation technology enabling the development of flexible, biocompatible implantable microelectrode arrays and devices used |
|for neurostimulation, in-vivo diagnostics as well as the development of low-cost, disposable microfluidics components and |
|sensors for in-vitro diagnostics. Products under development in collaboration with corporate and academic partners and |
|partially funded by SBIR grants form the NIH are microelectrode array devices for neural stimulation, in-vivo glucose sensors |
|and novel electrochemical immunosensors. |
[pic]
|ProteomTech, Inc. |David Hagebush |
|Emeryville, CA |Tel: 510-597-9131 |
| |Email: hagebush@protoemtech- |
| |dhagebush@ |
| |
|Therapeutics Research and Development: |
|Proteomtech, Inc. is a product-driven pharmaceutical research and development company. PTI is based upon IP for protein |
|refolding (US patent 6,583,268), Pt-Fold TM. |
| |
|Our focus and core technology is built around developing therapeutic proteins optimally refolded from E. coli inclusion bodies |
|that are difficult to recover via competing technologies. |
|Using Pt-Fold, ProteomTech has developed a pipeline of protein drug candidates. Proteomtech holds worldwide composition of |
|matter, method of manufacturing and methods of treating cancer patents for a protein therapeutic candidate for oncology, and has|
|submitted method of manufacturing patents for protein therapeutic candidates for chronic obstructive pulmonary disease and |
|thrombolytic indications. |
[pic]
|ProThera Biologics |Yow-Pin Lim |
|East Providence, RI |Tel: 401-301-2046 |
| |Email: Yow-Pin_Lim_MD@brown.edu |
| |
|ProThera Biologics develops "theranostic" and therapeutic products for serious human diseases such as sepsis and cancer. |
|Theranostics represent a new market area with enormous potential for growth which utilize predictive tests to make critical, |
|personalized treatment decisions. The company is currently focusing on novel uses of natural plasma protease inhibitors |
|(Inter-alpha inhibitors) which are involved in the pathological processes of systemic inflammation and cancer metastasis. |
|Utilizing inter-alpha inhibitors as integrated theranostic and therapeutic biomolecules, ProThera Biologics will target sepsis |
|and cancer, a clinical arena representing wide-spread patient populations with a significant unmet medical need. |
[pic]
|QED Labs |Pam Thuman-Commike |
|San Jose, CA |Tel: 408-295-8347 |
| |Email: pam@ |
| |
|QED Labs provides software for solving complex computational biology problems. We develop computational research tools for |
|three-dimensional structural determination from electron microscopy data that enable biologists, at all levels of structure |
|determination, to easily process their data. QED Labs accomplishes this with innovative software that guides user on how, when,|
|and why to perform data processing operation. |
[pic]
|Sci-Tec, Inc. |Val Golovlev |
|Knoxville, TN |Tel: 865-671-2166 |
| |Email: golovlev@ |
| |
|Sci-Tec, Inc. is a microarray technology company offering equipment, software, consumables and reagents for life science |
|research and biomedical applications. |
|Sci-Tec's core product is AuroGen microarray system, which has a unique capability to detect and quantify DNA, RNA and proteins |
|on high-density microarrays without chemical modification of target molecules. The unique, yet affordable microarray platform |
|can be used in various applications offering advantage of personal microarray system to researchers and medical practitioners |
|working in the fast expending fields of genetic analysis, medical diagnosis, environmental analysis, drug discovery, forensic |
|analysis, and biodefense. |
[pic]
|SibTech, Inc. |Joseph Backer |
|Newington, CT |Tel: 860-953-1164 |
| |Email: jbacker@ |
| |
|SibTech, Inc. is developing VEGF-based imaging constructs for targeting and imaging angiogenesis. The constructs for fluorescent|
|and nuclear medicine imaging, based on proprietary single-chain VEGF, are successful in animal models and strategies for |
|clinical development are being explored. In developing these constructs, SibTech utilized its proprietary technology for |
|conversion of biopharmaceutical proteins into the carriers of therapeutic and diagnostic agents. SibTech is offering this |
|technology for licensing and/or co-development to the companies that wish to expand applications and patent life of their |
|proprietary biopharmaceutical proteins. |
[pic]
|SoloHill Engineering, Inc. |Timothy Solomon |
|Ann Arbor, MI |Tel: 734-973-2956 |
| |Email: solohill@ |
| |
|SoloHill develops and delivers microcarrier technology for use in the human and animal pharmaceutical industries. SoloHill has |
|responded to industry needs over the past decade by developing animal protein free microcarriers, protocols for a variety of |
|cell culture based vaccines, and whole infected-cell harvest technology. |
|The Company’s protocols are for producing human influenza vaccine via cell culture technology in bioreactors using SoloHill’s |
|Hillex ® microcarriers, Vero or MDCK cell lines and, animal protein free media. SoloHill continues to seek partnerships and/or |
|licensing arrangements with pharmaceutical manufacturers that have an interest in utilizing microcarrier based cell culture |
|technologies. |
[pic]
|Source Signal Imaging, Inc. |Richard Greenblatt |
|San Diego, CA |Tel: 619-234-9935 |
| |Email: reg@ |
| |
|Source Signal Imaging (SSI) provides innovative, powerful, and useable software to measure and visualize human brain dynamics, |
|used by researchers and clinicians worldwide. SSI specializes in advanced signal and image processing, enabling investigators |
|to combine electroencephalography (EEG), magnetoencephalography (MEG) and magnetic resonance imaging (MRI) to determine where |
|events happen in the brain, how events change over time, and how brain regions interact. SSI’s EMSE® Suite software is used to |
|study cognition, perception, and memory. Diseases such as autism, schizophrenia, and epilepsy are characterized by disordered |
|brain dynamics, and EMSE® allows clinicians to better diagnose and understand these diseases. |
[pic]
|SpectraGenetics LLC |Cheryl Telmer |
|Pittsburgh, PA |Tel: 412-488-9350 |
| |Email: cheryl.telmer@ |
| |
|SpectraGenetics supplies the biomedical research market with innovative products for analyzing genes and gene function. The |
|company’s reporter-tagged full-length mammalian genes are sold to cell and molecular biologists in academic, government and |
|industrial laboratories. These products overcome many of the drawbacks of currently available reporter systems, leading to more |
|meaningful experimental data. The company’s Peptide Mass Signature Genotyping (PMSG) products provide sensitive, comprehensive |
|and accurate sequence information particularly suited to clinical cancer research where existing sequencing methods fail. |
|RT-PMSG products for studies of gene expression, including alternative splicing, provide complete characterization of variation |
|using a single kit. |
[pic]
|SpectRx Inc. |Shabbir Bambot |
|Norcross, GA |Tel: 847-491-3274 |
| |Email: sbambot@ |
| |
|SpectRx, Inc. (OTCBB: SPRX) uses innovative and minimally invasive technologies in products and product development activities |
|for the diagnosis and therapy of cancer and diabetes. The company is currently in FDA pivotal studies with its non-invasive |
|cervical cancer detection product and is commercializing this through its subsidiary, Guided Therapeutics, Inc. In the diabetes |
|arena, the company has innovative solutions for insulin delivery and glucose monitoring. SpectRx markets the SimpleChoice® line |
|of diabetes management products, which include insulin pump disposable supplies. SpectRx is also developing a consumer device |
|for continuous glucose monitoring. |
[pic]
|Synthasome |Anthony Ratcliffe |
|San Diego, CA |Tel: 858-490-9401 |
| |Email: anthonyratcliffe@ |
| |
| Synthasome is a biotechnology company developing regenerative medicine products primarily for musculoskeletal applications |
|(tendon, ligament and cartilage repair), using tissue engineering technologies supported by new intellectual property. The |
|Company uses federal research grants to drive early product development, and so far has received over $3 million in grants. The |
|first product in our pipeline is a device for assisting surgical repair of injured rotator cuff tendons (approx. $100 million |
|market), the product is anticipated to enter the market place in 2007, and will then be followed by products for knee articular |
|cartilage repair. |
[pic]
|SynVax, Inc. |Amrit Judd |
|North Logan, UT |Tel: 435- 713-4917 |
| |Email: synvax@ |
| |
|SynVax, Inc. is a biopharmaceutical company with a mission to successfully discover, develop, and commercialize pharmaceutical |
|products for use in infection, pain, and cardiology. At least five significant discoveries are currently ready for development,|
|and more are in the pipeline. Animal studies have been done on three products. The products are based on advanced peptide |
|structure-function analyses and expertise in peptide synthesis. Patent has been issued on one product and pending on another. |
|The pharmaceutical markets the company will address are currently in excess of $10 billion in annual sales. |
[pic]
|SynZyme Technologies, LLC |Carleton Hsia |
|Irvine, CA |Tel: 949-453-1072 |
| |Email: synzyme@ |
| |
|SynZyme Technologies, LLC, is a privately-held, California-based, Delaware biopharmaceutical company. Utilizing its proprietary |
|platform technology of polynitroxylation, SynZyme is engaged in the development of a drug pipeline based on targeted delivery of|
|caged nitric oxide free radical therapeutics. These products belong to a new class of stable, metal-free radicals with targeted |
|antioxidant and enzyme-mimetic activities, which are intended for the treatment of ischemia/reperfusion and inflammatory-related|
|diseases associated with inadequate blood flow. |
[pic]
|Talaria Inc |Peter Dunbar |
|Seattle, WA |Tel: 206-748-0443 |
| |Email: pjdunbar@ |
| |
|Talaria Inc has a proprietary “builder” that enables development of healthcare eLearning programs over the internet. This |
|enables our content developers to originate, modify and publish sophisticated eLearning programs from home or internet café |
|anywhere in the world yet have the functionality of a desktop or server application. |
|This technology drastically reduces our cost of development by reducing travel costs and improving workflow while also improving|
|quality of content, by enabling content experts from anywhere in the world to contribute without ever leaving home. Customers |
|delighted by Talaria products include the US Army, VA, major Pharmaceutical companies and hospitals. |
[pic]
|Talisman Limited |Paul Cumming |
|Vienna, VA |Tel: 703-938-0300 |
| |Email: pc@ |
| |
|The Quality Donor System (tm)(QDS), an FDA 510(k) cleared Medical Device, is Talisman's principal achievement. It may be the |
|world's only scientifically and medical production line proven automated multimedia blood donor health history interviewing |
|system. Since 2001 QDS has completed more than 450,000 interviews at five different blood and medical organizations and is |
|currently operating at the rate of 350,000 interviews/year. It runs on tablet computers in standalone or network/Web modes. It |
|has been shown repeatedly to vastly increase donor and staff satisfaction, reduce FDA errors by over 60% and staff time by over |
|80% and to increase donor honesty. |
[pic]
|Talking Lights LLC |Elmer Lupton |
|Boston, MA |Tel: 847-491-3275 |
| |Email: neil@talking- |
| |
|Talking Lights LLC uses existing lighting in a facility to create inexpensive unique communication networks and precise locator |
|capability. Lights become locator beacons while still providing non-flickering, strong illumination. Applications include |
|assistance for persons with cognitive disorders like Alzheimer's patients and traumatic brain injury patients, wayfinding and |
|guidance in retail facilities, office buildings, schools, hospitals and care facilities, and specialized assistive areas like|
|guidance for the blind. A capability like GPS indoors is created. |
[pic]
|Targeted Gene Delivery, Inc. |Steven Hefeneider |
|Portland, OR |Tel: 503-525-4878 |
| |Email: hefeneid@ohsu.edu |
| |
|Targeted Gene Delivery, Inc., develops immune regulatory therapeutics derived from bacterial and viral proteins. Bacteria and |
|viruses have the ability to encode proteins designed to regulate the host immune system. These proteins can be identified and |
|modified to form unique therapeutics able to either enhance or diminish the immune system. Therapeutics derived from these |
|proteins have the potential to alter the course of disease. Specific applications include anti-inflammatories for use in |
|chronic diseases such as septic shock and meningitis, and immune stimulatory products for use in immune compromised |
|individuals. Targeted Gene Delivery has developed a proprietary anti-inflammatory peptide with potential application in the |
|treatment of several chronic inflammatory diseases. The company is focused on the commercialization of this novel therapeutic, |
|and development of additional immune regulatory peptides. |
[pic]
|TechEn, Inc. |Arthur DiMartino |
|Milford, MA |Tel: 508-478-0042 |
| |Email: AAD@ |
| |
|TechEn designs, develops and markets non-invasive optical brain imaging solutions. The innovative, portable devices are sold |
|world-wide and provide fast quantitative assessment, reducing the cost for treatment and improving rehabilitation. Working in |
|conjunction with Harvard’s teaching hospital, MGH, TechEn has developed propriety real-time algorithms, hardware, software and |
|disposables. Current applications include: stroke rehabilitation, traumatic brain injury, autism, epilepsy and early child |
|development. |
|With twenty-two years experience in all stages of innovation, TechEn offers clients a full array of electronic product design |
|solutions and production services. Recent programs include Bone Densitometry, ICU Glucose Monitor, GPS Signal Simulator and |
|Wireless Biotech Sensing. |
[pic]
|The Virtual Reality Medical Center |Mark Wiederhold |
|San Diego, CA |Tel: 858-642-0267 |
| |Email: mwiederhold@ |
| |
|The Virtual Reality Medical Center (VRMC) delivers innovative pain distraction products using virtual reality technology |
|integrated with medical science. The patient wears a small, comfortable device with earphones and a 3-D visual display that |
|immerses them in an interactive world. Such immersion relieves pain by reducing attention to it. VRMC-developed worlds include |
|Enchanted Forest, Dream Castle, and others. These pain distraction products are important adjuncts to other pain management |
|methods, such as pharmaceuticals, because the patient is more in control of managing his or her pain relief, thus reducing |
|medication and visits to health professionals. |
[pic]
|Therapyx, Inc. |Thomas Conway |
|Buffalo, NY |Tel: 716-829-2528 |
| |Email: thomasc@ |
| |
|Therapyx, Inc. is a privately held biopharmaceutical company that focuses on the development and commercialization of |
|nanoadjuvants for innovative therapeutic and vaccination strategies. The company’s nanoadjuvant platform represents a general |
|strategy for the immunotherapy of disease through the application of slow-release |
|adjuvants. While the company’s first product is targeted for major cancers, including lung cancer (first indication), breast |
|cancer, melanoma and other solid tumors, Therapyx, Inc. has a broad pipeline of products at the pre-clinical stage for |
|applications in autoimmune |
|and infectious disease. |
[pic]
|Therataxis, LLC |Raghu Raghavan |
|Baltimore, MD |Tel: 410-464-1418 |
| |Email: raghu@ |
| |
|Therataxis models brain transport processes and designs delivery methods for therapies. The simulation and prediction of |
|transport mechanisms, and our proprietary direct delivery devices, provide the necessary link in developing successful |
|therapies of the brain by ensuring proper delivery. Our currently marketed products are surgical simulation software and |
|simulation-based device designs. We offer services in medical image analysis, biomedical simulations, therapy planning, and |
|management of appropriate research. In addition to our industrial customers, the company has academic partnerships with major |
|universities through grants and contracts. |
|Our focus is to improve delivery of therapeutics directly into brain and other solid tissue (prostate, tumor, etc.) by |
|predicting the distribution of the therapy - either particulate or energy - for a specific individual and disease state. |
[pic]
|Thromgen, Inc. |Alvin Schmaier |
|Cleveland, OH |Tel: 216-368-1172 |
| |Email: alvin.schmaier@case.edu |
| |
|Thromgen Inc., founded in 1995, is a privately owned early-stage biotechnology company that is discovering and developing novel |
|treatments for diseases related to a new class of thrombin receptor inhibitors (also called antagonists or blockers). The novel|
|mechanisms of the technology allows Thromgen’s therapeutic scope to include cardiovascular-, oncologic-, and |
|inflammatory-related diseases. Initially, the Company is focusing on acute coronary syndromes and prostate cancer with its lead|
|candidate, ThrombostatinTM. The Company is a spin-out from the University of Michigan (Ann Arbor) located in Ann Arbor, |
|Michigan. |
[pic]
|Tissue Technologies LLC |Irwin Cohen |
|Richmond, VA |Tel: 804-301-7839 |
| |Email: kelmanc@ |
| |
|Tissue Technologies LLC is a "start up" dedicated to healing and prevention of wounds. Our first product, a protease |
|sequestering dressing for chronic wounds is inexpensive and effective. We are developing other materials for the same purpose |
|which will be more potent and user friendly. Simiar products to treat gingivitis and ostony wound sites are planned. Also under|
|development is a bed-side color indicator for wound protease activity which will help the caregiver decide on therapy. In |
|addition, we have submitted a patent on a device to prevent pressure ulcers. The protease sequestration technology will apply |
|also to products to prevent skin aging. Finally, TT wound prodcuts will be for animals as well as man. |
[pic]
|TissueTech, Inc. & Bio-Tissue, Inc. |Amy Tseng |
|Miami, FL |Tel: 305-412-4430 |
| |Email: info@ |
| |
|TissueTech uses its proprietary cyro-preservation technologies to produce amniotic membrane tissue products with miraculous |
|properties in promoting anti-inflammatory, anti-scarring and anti-angiogenic actions. The Company’s two commercialized products |
|(AmniGraft® and ProKera™) are targeted to restore eye surface damages caused by corneal or conjunctival ulcers, chemical burns, |
|and pterygium, etc. With increasing number of publications since 1995, the concept of ocular surface reconstruction using these |
|products has gained popularity among ophthalmic community. This is proven by the exceptional growth the Company experienced last|
|year. The Company also has a pipeline includes several stem-cell therapies and novel medical devices at different stages of |
|development. The Company’s goal is to expand the therapeutic actions of its tissue-engineered products to other body sites in |
|the future. |
[pic]
|TRS Technologies, Inc. |Paul Rehrig |
|State College, PA |Tel: 814-238-7485 |
| |Email: paul@ |
| |
|TRS is a producer of specialty piezoelectric products for navy sonar, medical ultrasound, precision sensor, and precision |
|positioning markets. TRS has been an innovator in the area of piezoelectric materials technologies with developments such as |
|new materials for high power sonar projectors; machinable ceramics for the production of ultrasound arrays; high strength |
|ceramics for high force actuators; and single crystal piezoelectrics for broad band ultrasound transducers, high sensitivity |
|vibration sensors, and high displacement actuators. TRS currently has $4 million in annual sales and has received over $1 |
|million in investment capital for commercialization of new materials technologies. |
[pic]
|VeriFax Corporation |Ruth Shrairman |
|Boulder, CO |Tel: 303-581-9770 |
| |Email: shrairmr@ |
| |
|VeriFax is a Chapter S Colorado Corporation. It is a small R&D enterprise with the main mission to develop high quality, cost |
|effective security and biomedical devices based on IP developed by the company founders. The biomedical device “NeuroskillTM” is|
|intended to assess fine motor control fluctuations in people with neurological disorders, such as Parkinson’s disease and |
|stroke, while “ImpairscopeTM” is a device to assess impairment due to environmental intoxication and result of substance abuse. |
|The measures of impairment provided by Neuroskill and Impairscope can be considered as potential clinical markers for |
|prospective applications. The biometric device “AutographTM” offers an easy, cost-effective and universally accepted solution |
|for signature verification with unprecedented accuracy. It can be used in both cyber security and physical security |
|systems. |
[pic]
|Vesticon, Inc. |Cathryn Epley |
|Portland, OR |Tel: 503-230-0539 |
| |Email: cepley@ |
| |
|Vesticon is focused on the development of a suite of interelated solutions to make it easier and more lucrative for physicians |
|to deal with one of the most frustrating areas in medicine: the diagnosis and management of the dizzy patient. Building on the |
|assets of medical expertise that is among the most extensive for this field, Vesticon has funded operations through NIH SBIR |
|grants, which now provide a baseline to launch commercial activities to dominate the vestibular device market. Direct costs |
|related to injuries from elderly fallers with preventable vestibular problems exceed $10 billion; and Vesticon’s products will |
|penetrate a significant portion of this sector. |
[pic]
|Vical Incorporated |Marilyn Ferrari |
|San Diego, CA |Tel: 858-646-1135 |
| |Email: mferrari@ |
| |
|Vical's goal is to be an integrated biopharmaceutical company committed to the development and commercialization of vaccines and|
|immunotherapies based on its unique non-viral DNA technology. Together with its licensees and collaborators, Vical is currently |
|developing a number of vaccine and therapeutic protein product candidates for the prevention or treatment of infectious |
|diseases, cancer, and cardiovascular diseases. Independent development programs include vaccines for CMV and anthrax, as well as|
|novel immunotherapeutics for treatment of melanoma. Through collaborations with others, Vical leverages its technologies for |
|applications that may not be appropriate for independent product development efforts. Collaborators include Merck, Sanofi, |
|Merial (Merck/Sanofi animal health joint venture), Aqua Health (Novartis), AnGes MG, Corautus Genetics, and the NIH. In |
|addition, Vical pursues contract manufacturing opportunities to leverage its infrastructure and expertise in plasmid |
|manufacturing, and to provide revenues that contribute to its independent research and development efforts. |
[pic]
|VivaScan Corporation |Robert A. Peura |
|West Boylston, MA |Tel: 847-491-3278 |
| |Email: rpeura@ |
| |
|VivaScan Corporation has developed a painless testing device for blood glucose monitoring by means of unique noninvasive |
|infrared technology. Currently diabetic individuals stab themselves up to ten times per day to determine their blood glucose, |
|or inject insulin blindly at considerable risk of complications. VivaScan’s monitor, designed by a team of technical and |
|clinical experts, responds to the noninvasive test needs of diabetic persons. A proprietary platform technology has evolved |
|resulting in a personal hand held monitor. With the patented VivaScan glucose tester, a simple and gentle squeeze of the ear or |
|finger is all it takes to get an accurate reading of blood glucose. |
[pic]
|X-Ray Imaging Innovations |Gary Barnes |
|Birmingham, AL |Tel: 205-492-7555 |
| |Email: gtbarnes@ |
| |
|X-Ray Imaging Innovations is a company with expertise in medical x-ray imaging technology. The company's current efforts are |
|focused on the development of a novel bedside (portable) radiographic unit and in improving general radiography and digital |
|tomosynthesis. It is anticipated that the new portable x-ray unit will be easy to use and will result in markedly improved |
|images, images comparable in quality to those currently obtained with fixed general radiographic units. It is also anticipated |
|that the improvements we are working on in general radiography and digital tomosynthesis will improve image quality in a dose |
|efficient manner. |
................
................
In order to avoid copyright disputes, this page is only a partial summary.
To fulfill the demand for quickly locating and searching documents.
It is intelligent file search solution for home and business.
Related searches
- healthways participating fitness centers
- silversneakers participating locations
- zelle participating banks
- work number participating employer list
- the work number participating employers
- small cap tech companies 2019
- teach grant program participating schools
- fafsa participating schools
- large cap companies in india
- zelle participating credit unions
- work number participating employers
- ash participating provider directory